Member Info for NiptSteve

New interview with Lyn Rees below.

Re our market cap - "Rees believes it could grow beyond £500m". That will do!

https://flickread.com/edition/html/5e6f6fc477f53#53

I found it reassuring that they have enough of the materials that they need to support the growth in the core business and the new covid manufacturing and testing (considering the ongoing national debate about shortage of reagents and equipment etc).

Also that the lab in Taipei is also supporting the covid effort out there.

My question about when we could expect some further information re volumes of the covid business wasn't answered but hopefully we'll hear something soon.

The video is worth a watch all the way through if you can find the time - Re St George’s they are doing over 300 tests per month now from 20 ‘units’ and are onboarding a further 7 hospitals in the next couple of months to significantly increase the number of tests it does.

Nothing else that we don’t already know - Illumina test should be ready by end of Q1.

A question was asked re are we going to be funding new Illumina machines for existing customers and the answer was that most labs aren’t dedicated to a particular NGS and already have both NGS platforms.

We had a very brief trading update on 12/10 last year do i’d expect something similar.

I don’t think we’ll get test volumes but if we do i’d expect around 50k NIPT tests - no idea about the Elucigene side of things but I don’t expect much from that.

Unless a big jump in test volumes or actual contract news (June 2018 was last NIPT contract RNS) I can’t see much of a share price reaction.

So the recent Illumina court win vs Roche I would guess rules Roche and the Harmony test out of the running (again) for the NHS contract.

It seems a bit early for this rise to be down to the upcoming results - hopefully related to a long overdue contract announcement prior to results.

So NIPT is being rolled out all over the world and the NHS is now having to retender due to the legal challenge arising from the first tender!

The new tender will allow Roche (and the Harmony rest) to be considered as the microarray method along with NGS will now be considered.

Doesn’t really make much difference to us in the scheme of things as it’s only small volumes compared to rest of world but would have been nice to have had the winning bids revealed for this.

I still expect this to work out for us but can’t see any decision re NHS this side of Christmas.

https://phescreening.blog.gov.uk/2019/06/17/update-on-nipt-implementation-microarray-testing-technology-and-twins/

Just had a very quick look at his previous holding and I think he has actually increased his number of shares but is less percentage wise as a result of the acquisition. Looks like he has added a couple more million shares. Apologies if incorrect.

https://www.proactiveinvestors.co.uk/companies/stocktube/12507/yourgene-health--presses-the-reset-button--as-it-ramps-up-its-international-presence-12507.html

https://www.standard.co.uk/business/minnow-prenatal-test-specialist-yourgene-health-could-be-just-what-the-doctor-ordered-a4050701.html

France...

So it looks like NIPT testing has finally started to be reimbursed in France:

http://madame.lefigaro.fr/societe/le-depistage-de-la-trisomie-21-par-prise-de-sang-va-etre-rembourse-281218-162807

You'll have to rely on Google Translate but it says it could mean 58,000 tests per year are reimbursed - we have a strong presence in France via our distributor Adgenix so this should be good news for us.

Illumina...

Roche have defeated Illumina in the US - so it will be interesting to see how this impacts on how we approach the US, especially if as part of our settlement we have agreed to pay royalties on any US sales further down the line.

https://news.bloomberglaw.com/pharma-and-life-sciences/roche-ariosa-defeat-illumina-on-prenatal-dna-test-patents-1

Thailand...

Also another lab up and running in Thailand:

https://www.bumrungrad.com/en/women-center-health-obgyn-bangkok-thailand/procedures/non-invasive-prenatal-screening-nipt

Best of luck to all LTH with this for 2019.

I think they have gone from 15million to 11 million. We really could do with news soon to support and continue this share price rise.

Not material news as blood samples are being sent to Manchester but good to see IONA being offered in Germany via Elithia and marketed as the PreviaTest: https://eluthia.com

Most likely one of the unnamed Indian companies from a previous RNS. Here is a short interview from what appears the launch with SL in attendance: https://www.youtube.com/watch?v=sZmNnlCvZkA

Twix what is the proposed date for settlement hearing?

On the back of the India RNS I cannot see any need for a distressed sell. Test volumes, IMO, could be approaching 200k next year on current contracts alone. As painful as it has been to date (and I’m in this from the Vialogy days) I now would like to see this company grow and become profitable and achieve a sale price of 50p+

I quite liked that little phase of getting projected test volumes with new contracts however I would say the wording in today's RNS is the most positive I've seen. "2,000 cities and towns across India" "draw significant sample volumes from all over India" "material revenue growth" "test volumes ramp up to very significant levels" I'm in a positive kind of mood so lets say one test per week from each of those 2,000 locations and that gives us circa 100k tests per year from this contract alone. Just my own thoughts and speculation dyor etc.

Sorry I must have missed that he already had a holding so not as interesting/significant as I thought.

So a Steven Myers now holds 4.1% of the company - that’s a big stake so must have a lot of confidence at this level.

Agree Twix. My initial reaction was ffs no resolution but if settlement details are being discussed they must be realistic otherwise we would surely have just pulled out of UK as suggested. I can’t think of any other motivator for Illumina now being willing to potentially settle other than the EU investigation.

Trading update � real underlying momentum The FY 2018 illustrates the strong momentum in the business. The Non Invasive Pregnancy Testing (NIPT) business has started FY 2019 at EBITDA-breakeven with annualised revenues running at �7.7m (+24% up on FY 2018). This excludes growth from existing customers yet to come on stream, the benefit of national reimbursement coverage to NIPT volumes in France (expected H2 2018) and new customer wins in high-volume markets that will be accessible due to new technology that affords a lower-priced NIPT (eg. India). The company also raised �2.5m by way of a placing at 4.5p, which is expected to be sufficient to get to cashflow-breakeven for the group as a whole. Although there remains the uncertainty of litigation with Illumina, the fact that Premaitha is in settlement discussions is positive, whilst growth initiatives are predominantly focused on territories where problematic IP is not in force (67% of revenues). We reinstate forecasts and a target price of 12p. https://www.finncap.com/news-insight/finncap-research-company-notes-15-may-2018